Evidence map›Paper›PMID 43011533›Full record

ArticleBrain communications2026

Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation.

Clara O Sailer, Sophia Lengsfeld, David Coynel, Davide Zanchi, Nica Jeanloz, Fabienne Baur, Cemile Bathelt, Katja Bologna, Tanja Vukajlovic, Sandrine A Urwyler and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Clara O SailerDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0001-6439-8191
Sophia LengsfeldDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
David CoynelDivision of Cognitive Neuroscience, Department of Biomedicine, University of Basel, 4055 Basel, Switzerland.ORCID https://orcid.org/0000-0001-5028-5807
Davide ZanchiF. Hoffmann- La Roche, Roche Innovation Centre Basel, 4070 Basel, Switzerland.
Nica JeanlozDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
Fabienne BaurDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
Cemile BatheltDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
Katja BolognaDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
Tanja VukajlovicDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
Sandrine A UrwylerDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
Mirjam Christ-CrainDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-6336-0965
Bettina WinzelerDepartment of Clinical Research, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0001-8305-2700

Funding

TRAINING GRANT IN ACADEMIC ENDOCRINOLOGYT32DK007529 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Ursula B. Kaiser, Anand Vaidya · 1986 to 2026
$6.3M
NIDDK NIH HHS T32 DK007529
6 · The paper itself

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are investigated for treating addiction. However, it remains unclear whether these agents modulate addiction-related neural circuitry. To address this question, we conducted a predefined neuroimaging subtrial of a larger randomized placebo-controlled trial. While the parent trial enrolled 255 participants with at least moderate nicotine dependence, this mechanistic study included a subset of 71 participants. Participants were randomized to receive either 1.5 mg dulaglutide (

Indexed as

craving for cigarettesGLP-1 receptor agonistsnicotine addictionrewardvarenicline

Identifiers

PMID43011533
PMCPMC13748752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.